CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 33,512 Shares

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 33,512 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $25.03, for a total transaction of $838,805.36. Following the completion of the transaction, the chief financial officer owned 148,121 shares in the company, valued at approximately $3,707,468.63. The trade was a 18.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Stock Down 2.3%

Shares of CeriBell stock traded down $0.58 during trading on Thursday, hitting $24.31. 262,277 shares of the stock traded hands, compared to its average volume of 469,652. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The stock’s fifty day simple moving average is $19.43 and its 200 day simple moving average is $19.19. The firm has a market cap of $933.02 million, a P/E ratio of -13.81 and a beta of 0.81. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The business had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. On average, equities analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Strs Ohio acquired a new stake in shares of CeriBell during the first quarter worth about $27,000. Caitong International Asset Management Co. Ltd increased its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell in the 3rd quarter worth approximately $33,000. CWM LLC raised its position in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the period.

Analyst Upgrades and Downgrades

CBLL has been the subject of several recent research reports. Barclays raised CeriBell to a “neutral” rating in a research report on Tuesday. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. BTIG Research increased their price target on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Canaccord Genuity Group boosted their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and a consensus target price of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.